Femasys Inc. (NASDAQ: FEMY) Stock Competitors & Peer Comparison
See FEMY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for FEMY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FEMY | $2.10 | -2.78% | 6.4M | -0.47 | -$4.49 | N/A |
| ISRG | $401.24 | -1.33% | 141.7B | 41.71 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.22% |
| BDX | $178.07 | -0.52% | 49.1B | 13.70 | $13.00 | +2.22% |
| RMD | $221.15 | +0.02% | 32.1B | 20.54 | $10.77 | +1.10% |
| MDLN | $34.94 | +0.69% | 29.5B | 25.60 | $1.36 | N/A |
| WST | $365.01 | -1.55% | 25.7B | 42.94 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $87.77 | -0.43% | 15.2B | 12.36 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.22% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
FEMY vs ISRG Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, ISRG has a market cap of 141.7B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while ISRG trades at $401.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas ISRG's P/E ratio is 41.71. In terms of profitability, FEMY's ROE is -2.26%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, FEMY is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
FEMY vs BDXA Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas BDXA's P/E ratio is 45.70. In terms of profitability, FEMY's ROE is -2.26%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, FEMY is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
FEMY vs BDX Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, BDX has a market cap of 49.1B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while BDX trades at $178.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas BDX's P/E ratio is 13.70. In terms of profitability, FEMY's ROE is -2.26%, compared to BDX's ROE of +0.04%. Regarding short-term risk, FEMY is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
FEMY vs RMD Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, RMD has a market cap of 32.1B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while RMD trades at $221.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas RMD's P/E ratio is 20.54. In terms of profitability, FEMY's ROE is -2.26%, compared to RMD's ROE of +0.24%. Regarding short-term risk, FEMY is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
FEMY vs MDLN Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, MDLN has a market cap of 29.5B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while MDLN trades at $34.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas MDLN's P/E ratio is 25.60. In terms of profitability, FEMY's ROE is -2.26%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, FEMY is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
FEMY vs WST Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while WST trades at $365.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas WST's P/E ratio is 42.94. In terms of profitability, FEMY's ROE is -2.26%, compared to WST's ROE of +0.19%. Regarding short-term risk, FEMY is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
FEMY vs HOLX Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas HOLX's P/E ratio is 31.54. In terms of profitability, FEMY's ROE is -2.26%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, FEMY is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
FEMY vs SOLV Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, SOLV has a market cap of 15.2B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while SOLV trades at $87.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas SOLV's P/E ratio is 12.36. In terms of profitability, FEMY's ROE is -2.26%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, FEMY is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
FEMY vs BDXB Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas BDXB's P/E ratio is 7.60. In terms of profitability, FEMY's ROE is -2.26%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, FEMY is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
FEMY vs BAX Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, BAX has a market cap of 12.2B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while BAX trades at $23.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas BAX's P/E ratio is 11.36. In terms of profitability, FEMY's ROE is -2.26%, compared to BAX's ROE of -0.17%. Regarding short-term risk, FEMY is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
FEMY vs COO Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, COO has a market cap of 11.2B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while COO trades at $57.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas COO's P/E ratio is 12.59. In terms of profitability, FEMY's ROE is -2.26%, compared to COO's ROE of +0.07%. Regarding short-term risk, FEMY is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
FEMY vs AVTR Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, AVTR has a market cap of 10.2B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while AVTR trades at $15.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas AVTR's P/E ratio is 17.69. In terms of profitability, FEMY's ROE is -2.26%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, FEMY is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
FEMY vs RGEN Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, RGEN has a market cap of 10B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while RGEN trades at $177.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas RGEN's P/E ratio is 98.46. In terms of profitability, FEMY's ROE is -2.26%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, FEMY is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
FEMY vs ATR Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, ATR has a market cap of 7.7B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while ATR trades at $120.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas ATR's P/E ratio is 21.14. In terms of profitability, FEMY's ROE is -2.26%, compared to ATR's ROE of +0.14%. Regarding short-term risk, FEMY is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
FEMY vs BLCO Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while BLCO trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas BLCO's P/E ratio is 26.07. In terms of profitability, FEMY's ROE is -2.26%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, FEMY is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
FEMY vs TFX Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, TFX has a market cap of 5.6B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while TFX trades at $126.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas TFX's P/E ratio is 14.41. In terms of profitability, FEMY's ROE is -2.26%, compared to TFX's ROE of -0.32%. Regarding short-term risk, FEMY is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
FEMY vs STVN Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while STVN trades at $19.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas STVN's P/E ratio is 30.23. In terms of profitability, FEMY's ROE is -2.26%, compared to STVN's ROE of +0.09%. Regarding short-term risk, FEMY is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
FEMY vs MMSI Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while MMSI trades at $86.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas MMSI's P/E ratio is 22.03. In terms of profitability, FEMY's ROE is -2.26%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, FEMY is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
FEMY vs ICUI Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while ICUI trades at $157.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas ICUI's P/E ratio is 19.62. In terms of profitability, FEMY's ROE is -2.26%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, FEMY is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
FEMY vs NVST Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, NVST has a market cap of 3.8B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while NVST trades at $23.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas NVST's P/E ratio is 15.76. In terms of profitability, FEMY's ROE is -2.26%, compared to NVST's ROE of +0.03%. Regarding short-term risk, FEMY is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
FEMY vs PLSE Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, PLSE has a market cap of 3.4B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while PLSE trades at $49.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas PLSE's P/E ratio is -42.23. In terms of profitability, FEMY's ROE is -2.26%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, FEMY is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
FEMY vs ATRC Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, ATRC has a market cap of 2.7B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while ATRC trades at $53.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas ATRC's P/E ratio is 1664.29. In terms of profitability, FEMY's ROE is -2.26%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, FEMY is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check ATRC's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
FEMY vs LMAT Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while LMAT trades at $80.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas LMAT's P/E ratio is 29.48. In terms of profitability, FEMY's ROE is -2.26%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, FEMY is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
FEMY vs BLFS Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while BLFS trades at $36.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas BLFS's P/E ratio is 35.71. In terms of profitability, FEMY's ROE is -2.26%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, FEMY is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check BLFS's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
FEMY vs XRAY Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, XRAY has a market cap of 1.8B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while XRAY trades at $8.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas XRAY's P/E ratio is 6.11. In terms of profitability, FEMY's ROE is -2.26%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, FEMY is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check XRAY's competition here
Azenta, Inc. (NASDAQ: AZTA)
FEMY vs AZTA Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, AZTA has a market cap of 1.6B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while AZTA trades at $34.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas AZTA's P/E ratio is 82.10. In terms of profitability, FEMY's ROE is -2.26%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, FEMY is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
FEMY vs KMTS Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while KMTS trades at $27.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas KMTS's P/E ratio is -10.23. In terms of profitability, FEMY's ROE is -2.26%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, FEMY is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
FEMY vs STAA Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while STAA trades at $22.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas STAA's P/E ratio is 39.26. In terms of profitability, FEMY's ROE is -2.26%, compared to STAA's ROE of +0.01%. Regarding short-term risk, FEMY is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
FEMY vs ATRI Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas ATRI's P/E ratio is 64.50. In terms of profitability, FEMY's ROE is -2.26%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, FEMY is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
FEMY vs ANGO Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, ANGO has a market cap of 624.9M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while ANGO trades at $15.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas ANGO's P/E ratio is -38.77. In terms of profitability, FEMY's ROE is -2.26%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, FEMY is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
FEMY vs EMBC Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, EMBC has a market cap of 343.5M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while EMBC trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas EMBC's P/E ratio is 2.23. In terms of profitability, FEMY's ROE is -2.26%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, FEMY is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
FEMY vs SMTI Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, SMTI has a market cap of 320.7M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while SMTI trades at $34.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas SMTI's P/E ratio is -581.33. In terms of profitability, FEMY's ROE is -2.26%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, FEMY is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check SMTI's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
FEMY vs NNNN Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, NNNN has a market cap of 274.3M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while NNNN trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas NNNN's P/E ratio is 38.18. In terms of profitability, FEMY's ROE is -2.26%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, FEMY is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
FEMY vs OSUR Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, OSUR has a market cap of 267.1M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while OSUR trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas OSUR's P/E ratio is -5.62. In terms of profitability, FEMY's ROE is -2.26%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, FEMY is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
FEMY vs UTMD Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, UTMD has a market cap of 236.7M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while UTMD trades at $74.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas UTMD's P/E ratio is 22.00. In terms of profitability, FEMY's ROE is -2.26%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, FEMY is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
FEMY vs PDEX Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, PDEX has a market cap of 208.7M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while PDEX trades at $65.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas PDEX's P/E ratio is 15.83. In terms of profitability, FEMY's ROE is -2.26%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, FEMY is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
FEMY vs KRMD Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, KRMD has a market cap of 138.7M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while KRMD trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas KRMD's P/E ratio is -75.50. In terms of profitability, FEMY's ROE is -2.26%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, FEMY is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
FEMY vs STXS Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, STXS has a market cap of 116.5M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while STXS trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas STXS's P/E ratio is -7.00. In terms of profitability, FEMY's ROE is -2.26%, compared to STXS's ROE of -1.33%. Regarding short-term risk, FEMY is more volatile compared to STXS. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
FEMY vs AKYA Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas AKYA's P/E ratio is -1.34. In terms of profitability, FEMY's ROE is -2.26%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, FEMY is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
FEMY vs DXR Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, DXR has a market cap of 64.1M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while DXR trades at $10.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas DXR's P/E ratio is 8.93. In terms of profitability, FEMY's ROE is -2.26%, compared to DXR's ROE of +0.13%. Regarding short-term risk, FEMY is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
FEMY vs STSS Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas STSS's P/E ratio is -0.02. In terms of profitability, FEMY's ROE is -2.26%, compared to STSS's ROE of -1.54%. Regarding short-term risk, FEMY is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
FEMY vs OMIC Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas OMIC's P/E ratio is -0.58. In terms of profitability, FEMY's ROE is -2.26%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, FEMY is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
FEMY vs IGAP Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas IGAP's P/E ratio is -10.52. In terms of profitability, FEMY's ROE is -2.26%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, FEMY is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
FEMY vs POCI Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, POCI has a market cap of 46.7M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while POCI trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas POCI's P/E ratio is -6.78. In terms of profitability, FEMY's ROE is -2.26%, compared to POCI's ROE of -0.24%. Regarding short-term risk, FEMY is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check POCI's competition here
Nephros, Inc. (NASDAQ: NEPH)
FEMY vs NEPH Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, NEPH has a market cap of 39.8M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while NEPH trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas NEPH's P/E ratio is 61.17. In terms of profitability, FEMY's ROE is -2.26%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, FEMY is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check NEPH's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
FEMY vs HBIO Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, HBIO has a market cap of 36.7M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while HBIO trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas HBIO's P/E ratio is -22.58. In terms of profitability, FEMY's ROE is -2.26%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, FEMY is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
FEMY vs MLSS Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, MLSS has a market cap of 35.8M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while MLSS trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas MLSS's P/E ratio is -8.10. In terms of profitability, FEMY's ROE is -2.26%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, FEMY is more volatile compared to MLSS. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
FEMY vs SDC Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas SDC's P/E ratio is -0.03. In terms of profitability, FEMY's ROE is -2.26%, compared to SDC's ROE of -1.96%. Regarding short-term risk, FEMY is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
FEMY vs IVC Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas IVC's P/E ratio is -0.79. In terms of profitability, FEMY's ROE is -2.26%, compared to IVC's ROE of -0.46%. Regarding short-term risk, FEMY is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
FEMY vs RVP Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, RVP has a market cap of 20.5M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas RVP's P/E ratio is -5.70. In terms of profitability, FEMY's ROE is -2.26%, compared to RVP's ROE of -0.05%. Regarding short-term risk, FEMY is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
FEMY vs BNGO Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, BNGO has a market cap of 18M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while BNGO trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas BNGO's P/E ratio is -0.52. In terms of profitability, FEMY's ROE is -2.26%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, FEMY is more volatile compared to BNGO. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
FEMY vs ZJYL Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, ZJYL has a market cap of 15.7M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while ZJYL trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas ZJYL's P/E ratio is 13.68. In terms of profitability, FEMY's ROE is -2.26%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, FEMY is more volatile compared to ZJYL. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
FEMY vs RGNT Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, RGNT has a market cap of 12.8M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while RGNT trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas RGNT's P/E ratio is -0.08. In terms of profitability, FEMY's ROE is -2.26%, compared to RGNT's ROE of N/A. Regarding short-term risk, FEMY is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
FEMY vs CUPR Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, CUPR has a market cap of 6.7M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while CUPR trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas CUPR's P/E ratio is -1.80. In terms of profitability, FEMY's ROE is -2.26%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, FEMY is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check CUPR's competition here
Lucyd, Inc (NASDAQ: LUCY)
FEMY vs LUCY Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, LUCY has a market cap of 5.8M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while LUCY trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas LUCY's P/E ratio is -0.71. In terms of profitability, FEMY's ROE is -2.26%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, FEMY is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
FEMY vs NSTG Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas NSTG's P/E ratio is -0.03. In terms of profitability, FEMY's ROE is -2.26%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, FEMY is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
FEMY vs POAI Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas POAI's P/E ratio is -0.38. In terms of profitability, FEMY's ROE is -2.26%, compared to POAI's ROE of -21.19%. Regarding short-term risk, FEMY is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
FEMY vs MHUA Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas MHUA's P/E ratio is 0.25. In terms of profitability, FEMY's ROE is -2.26%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, FEMY is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
FEMY vs GMVD Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas GMVD's P/E ratio is -0.01. In terms of profitability, FEMY's ROE is -2.26%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, FEMY is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
FEMY vs GMVDW Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas GMVDW's P/E ratio is N/A. In terms of profitability, FEMY's ROE is -2.26%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, FEMY is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
FEMY vs AVGR Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas AVGR's P/E ratio is -0.05. In terms of profitability, FEMY's ROE is -2.26%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, FEMY is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
FEMY vs NXGL Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, NXGL has a market cap of 1.5M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while NXGL trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas NXGL's P/E ratio is -0.25. In terms of profitability, FEMY's ROE is -2.26%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, FEMY is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check NXGL's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
FEMY vs NXGLW Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, NXGLW has a market cap of 1.3M. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, FEMY's ROE is -2.26%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, FEMY is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
FEMY vs LUCYW Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas LUCYW's P/E ratio is N/A. In terms of profitability, FEMY's ROE is -2.26%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, FEMY is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for FEMY.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
FEMY vs APR Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, APR has a market cap of 0. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas APR's P/E ratio is 22.59. In terms of profitability, FEMY's ROE is -2.26%, compared to APR's ROE of +9.81%. Regarding short-term risk, FEMY is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check APR's competition here
Invuity, Inc. (NASDAQ: IVTY)
FEMY vs IVTY Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas IVTY's P/E ratio is -3.80. In terms of profitability, FEMY's ROE is -2.26%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, FEMY is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
FEMY vs ATRS Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas ATRS's P/E ratio is 14.95. In terms of profitability, FEMY's ROE is -2.26%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, FEMY is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check ATRS's competition here
Analogic Corporation (NASDAQ: ALOG)
FEMY vs ALOG Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas ALOG's P/E ratio is 40.93. In terms of profitability, FEMY's ROE is -2.26%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, FEMY is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check ALOG's competition here
IntriCon Corporation (NASDAQ: IIN)
FEMY vs IIN Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, IIN has a market cap of 0. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas IIN's P/E ratio is 226.45. In terms of profitability, FEMY's ROE is -2.26%, compared to IIN's ROE of -0.00%. Regarding short-term risk, FEMY is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
FEMY vs HRC Comparison October 2026
Femasys Inc. (NASDAQ: FEMY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FEMY stands at 6.4M. In comparison, HRC has a market cap of 0. Regarding current trading prices, FEMY is priced at $2.10 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FEMY currently has a P/E ratio of -0.47, whereas HRC's P/E ratio is 41.92. In terms of profitability, FEMY's ROE is -2.26%, compared to HRC's ROE of +0.14%. Regarding short-term risk, FEMY is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for FEMY.Check HRC's competition here